Pirfenidone-Induced Photosensitive Dermatitis: A Rare Side Effect

Saleem, Ramsha; Vaidya, Sachin

doi:10.7759/cureus.15200

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 22 patients from 20 studies were included (Table 1). 10–28 Of these patients, 15 patients were males, and 2 patients were females. The sex of 5 patients was not described in the articles.…”

Section: Resultsmentioning

confidence: 99%

“…Of these patients, 13 patients were given local glucocorticoid therapy, and 10 patients were given systemic glucocorticoid therapy. Four patients switched to other drugs, such as acetylcysteine, nintedanib, cyclosporine and hydroxychloroquine 16,19,22,29 . In addition, 2 patients were given antihistamines, 12,14 and other local treatments, including silver sulfadiazine and pimecrolimus, were administered to one patient 21,24 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective analysis of skin photosensitivity induced by pirfenidone

Wang

Sun

et al. 2021

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objective Knowledge regarding the association between photosensitivity and pirfenidone is based mainly on case reports. The purpose of this article was to evaluate the clinical characteristics of photosensitivity associated with pirfenidone. Methods We collected studies on photosensitivity induced by pirfenidone published from 2008 to 31 August 2021 in Chinese and English for a retrospective analysis. Results and discussion The median age was 70 years (range 57–80) in 22 patients with pirfenidone‐induced photosensitivity. The dose at the onset of symptoms ranged from 600 to 2403 mg for the treatment of idiopathic pulmonary fibrosis. Pirfenidone‐induced photosensitivity occurred within 1 week in some patients and up to 8 months in others. The most common clinical manifestation of photosensitivity caused by pirfenidone was itching on body parts exposed to sunlight (back of hands, face, neck, and limbs) in 15 patients followed by erythema in 13 patients. Histopathological examination revealed necrotic keratinocytes, lymphocytic inflammatory cell infiltrate, hyperkeratosis and liquefaction degeneration in 5 patients. The photosensitivity test showed a markedly decreased minimum erythema dose (MED) of 7–228 mJ/cm2 UV‐B in 4 patients and 4.86–12 J/cm2 UV‐A in 5 patients. The clinical symptoms were significantly improved or completely relieved with a median time of 4 weeks (range 1–8) after drug withdrawal, dose reduction or systemic and topical glucocorticoid therapy. What is new and conclusion Clinicians should be aware of the potential phototoxic effects of pirfenidone and should inform patients to take pirfenidone during (or after) a meal, avoid sun exposure, wear protective clothing, and apply broad‐spectrum sunscreen with high ultraviolet UVA and UVB protection.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Retrospective analysis of skin photosensitivity induced by pirfenidone

Wang

Sun

et al. 2021

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

show abstract

“…While there have been multiple reported cases of pirfenidone-induced phototoxic effect, the mechanism of phototoxicity remains unclear [6][7][8]. A study by Seto et al discusses in vitro evidence of phototoxicity via generation of reactive oxygen species (ROS) via peroxidation of photodynamic lipids and cleavage of DNA due to exposure to sunlight [9].…”

Section: Discussionmentioning

confidence: 99%

Severe Photosensitivity Reaction After Pirfenidone Use

Choudhury¹,

Taweesedt²,

Dadhwal³

et al. 2021

Cureus

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis is a chronic and progressive disease with a significant mortality rate. Pirfenidone is one of two oral antifibrotic therapies approved to treat idiopathic pulmonary fibrosis (IPF). Pirfenidone helps decrease disease progression in patients with IPF and reduces vital capacity. This has led to widespread use of this medication in recent years. In this case report, we present a 60-year-old male who started treatment with pirfenidone for IPF and had severe skin reactions after initiation of therapy.

show abstract